Strides Arcolab Limited has bagged two ANDA approvals for adenosine injection USP, 3 mg/mL, packaged in 6 mg/2 mL single dose vials and meloxicam tablets USP, 7.5 mg and 15 mg.
The approval of adenosine injection takes total sterile products approvals to 16 and meloxicam tablets takes total oral products approvals to 12.
According to V S Iyer, CEO, India Operations, the continued flow of speedy regulatory approvals, demonstrates our strength in manufacturing and R&D.
While adenosine injection is a cardiovascular agent and is the generic equivalent of Adenocard of Astellas Pharma Inc and meloxicam tablets is a non-steroidal anti-inflammatory agent which is a the generic equivalent of Mobic of Boehringer Ingelheim Pharmaceuticals, Inc.
Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for penicillin and penems, cepahlosporins, oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. It operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth.